Novel therapies for Helicobacter pylori infection.
Aliment Pharmacol Ther
; 13(1): 35-42, 1999 Jan.
Article
em En
| MEDLINE
| ID: mdl-9892877
ABSTRACT
BACKGROUND:
Increasing antibiotic resistance has begun to impair our ability to cure Helicobacter pylori infection.AIM:
To evaluate orally administered novel therapies for the treatment of H. pylori infection.METHODS:
Healthy H. pylori infected volunteers received (a) hyperimmune bovine colostral immune globulins, (b) an oligosaccharide containing an H. pylori adhesion target, Neu5Aca2-3Galb1-4Glc-(3'-sialyllactose), or (c) recombinant human lactoferrin. Outcome was assessed by urea breath test or histological assessment of the number of H. pylori present.RESULTS:
None of the novel therapies appeared effective and no adverse events occurred.CONCLUSION:
Although in vitro data appeared promising, in vivo results were disappointing. Higher doses, longer duration of therapy, adjunctive acid suppression, or a combination could possibly yield better results.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Ácidos Siálicos
/
Imunoglobulina G
/
Adjuvantes Imunológicos
/
Helicobacter pylori
/
Infecções por Helicobacter
/
Lactoferrina
/
Lactose
/
Antiulcerosos
Limite:
Adult
/
Aged
/
Animals
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Aliment Pharmacol Ther
Assunto da revista:
FARMACOLOGIA
/
GASTROENTEROLOGIA
/
TERAPIA POR MEDICAMENTOS
Ano de publicação:
1999
Tipo de documento:
Article
País de afiliação:
Estados Unidos